CEO Lori Woods with Proactive on the pending merger with Viewpoint Molecular Targeting

Dec 7, 2022

Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session

Feb 23, 2023

The result from first patient dosed with VMT-α-NET in India on a compassionate use basis showed favorable responses. The initial response was...

Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022

Feb 16, 2023

Fiscal Calendar Year Changes from June to December Year End RICHLAND, WASHINGTON & CORALVILLE, IOWA – February 16, 2023 Perspective,...

Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

Feb 7, 2023

Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and...

CEO Lori Woods with Proactive on the pending merger with Viewpoint Molecular Targeting

Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session

Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022

Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

Patients & Families

Doctors & Clinicians

Our company

Patients & Families

Doctors & Clinicians

Our Company